Last updated: 20 May 2024 at 4:20pm EST

Peter N Kellogg Net Worth




The estimated Net Worth of Peter N Kellogg is at least $7.6 million dollars as of 4 May 2018. Peter Kellogg owns over 3,500 units of Merck & Co Inc stock worth over $5,830,824 and over the last 21 years Peter sold MRK stock worth over $1,767,332.

Peter Kellogg MRK stock SEC Form 4 insiders trading

Peter has made over 20 trades of the Merck & Co Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Peter exercised 3,500 units of MRK stock worth $401,485 on 4 May 2018.

The largest trade Peter's ever made was exercising 60,000 units of Merck & Co Inc stock on 31 July 2017 worth over $6,882,600. On average, Peter trades about 3,903 units every 46 days since 2003. As of 4 May 2018 Peter still owns at least 50,831 units of Merck & Co Inc stock.

You can see the complete history of Peter Kellogg stock trades at the bottom of the page.



What's Peter Kellogg's mailing address?

Peter's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.

Insiders trading at Merck & Co Inc

Over the last 15 years, insiders at Merck & Co Inc have traded over $138,980,380 worth of Merck & Co Inc stock and bought 48,209 units worth $1,563,736 . The most active insiders traders include Wendell P Weeks, Kenneth C Frazier et Douglas M Jr Baker. On average, Merck & Co Inc executives and independent directors trade stock every 15 days with the average trade being worth of $5,050,222. The most recent stock trade was executed by Chirfi Guindo on 5 August 2024, trading 36,901 units of MRK stock currently worth $4,250,995.



What does Merck & Co Inc do?

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.



Complete history of Peter Kellogg stock trades at Alnylam Pharmaceuticals Inc, Biogen Inc, Yield10 Bioscience Inc et Merck & Co Inc

Initié
Trans.
Transaction
Prix ​​total
Peter N Kellogg
Exec. V.P. et C.F.O
Exercice d'option $1,893,600
13 Nov 2013
Peter N Kellogg
Exec. V.P. et C.F.O
Exercice d'option $1,678,879
6 May 2013
Peter N Kellogg
Exec. V.P. et C.F.O
Exercice d'option $671,639
24 Apr 2012
Peter N Kellogg
Exec. V.P. et C.F.O
Acheter $502,440
12 Aug 2011
Peter N Kellogg
Exec. V.P. et C.F.O
Exercice d'option $381,069
28 Feb 2011
Peter N Kellogg
Exec. V.P. et C.F.O
Exercice d'option $1,388,400
13 Nov 2010
Peter N Kellogg
Vice-président exécutif et Directeur des finances
Vente $322,569
20 Mar 2007
Peter N Kellogg
Vice-président exécutif et Directeur des finances
Vente $502,142
13 Feb 2007
Peter N Kellogg
Vice-président exécutif et Directeur des finances
Exercice d'option $417,654
6 Feb 2007
Peter N Kellogg
Vice-président exécutif et Directeur des finances
Vente $942,621
19 Sep 2006


Merck & Co Inc executives and stock owners

Merck & Co Inc executives and other stock owners filed with the SEC include: